Parathyroid cancer screening: Difference between revisions
Jump to navigation
Jump to search
(Created page with "__NOTOC__ {{Parathyroid cancer}} {{CMG}}; {{AE}} {{Ammu}} ==Overview== ==Screening== ==References== {{reflist|2}} Category:Templates {{WikiDoc Help Menu}} {{WikiDoc So...") |
No edit summary |
||
| Line 5: | Line 5: | ||
==Screening== | ==Screening== | ||
* Germline DNA analysis for HRPT2/CDC73 is recommended among patients with parathyroid cancer, as early detection can benefit relatives and offsprings. | |||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
Revision as of 18:07, 23 December 2015
|
Parathyroid cancer Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Parathyroid cancer screening On the Web |
|
American Roentgen Ray Society Images of Parathyroid cancer screening |
|
Risk calculators and risk factors for Parathyroid cancer screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]
Overview
Screening
- Germline DNA analysis for HRPT2/CDC73 is recommended among patients with parathyroid cancer, as early detection can benefit relatives and offsprings.